modelPrilocaineCombinations
Extends from Pharmacolibrary.Drugs.ATC.N.N01BB54.
Information
| name: | PrilocaineCombinations | |
| ATC code: | N01BB54 | route: | topical |
| compartments: | 1 | |
| dosage: | 1000 | mg |
| volume of distribution: | 1.6 | L |
| clearance: | 48 | mL/min/kg |
| other parameters in model implementation | ||
Prilocaine is a local anesthetic of the amide type, commonly used for infiltration anesthesia, nerve block, and in combination with other anesthetics such as lidocaine for topical or regional anesthesia. It is used to cause loss of sensation during minor surgical procedures and dental work. The fixed combination with lidocaine (under trade name EMLA) is widely approved for topical anesthesia of the skin.
Pharmacokinetics
Estimated pharmacokinetics in healthy adult subjects, typical topical application (EMLA) on intact skin. Published reports for prilocaine combinations are sparse; parameters are based on mean values reported for prilocaine in topical lidocaine-prilocaine formulation.
References
Tran, AN, & Koo, JY (2014). Risk of systemic toxicity with topical lidocaine/prilocaine: a review. Journal of drugs in dermatology : JDD 13(9) 1118–1122. PUBMED:https://pubmed.ncbi.nlm.nih.gov/25226014
Li, L, et al., & Ma, P (2023). Dermal effects and pharmacokinetic evaluation of the lidocaine/prilocaine cream in healthy Chinese volunteers. BMC pharmacology & toxicology 24(1) 51–None. DOI:10.1186/s40360-023-00690-x PUBMED:https://pubmed.ncbi.nlm.nih.gov/37828535
Wang, F, et al., & Li, H (2023). Safety and Pharmacokinetics of PSD502 in Healthy Chinese Male and Female Volunteers: Two Randomized, Double-Blind, Placebo-Controlled, Phase I Trials. Clinical drug investigation 43(7) 503–515. DOI:10.1007/s40261-023-01277-4 PUBMED:https://pubmed.ncbi.nlm.nih.gov/37380910
Parameters
| Type | Name | Default | Description |
|---|---|---|---|
| Modelica.Units.SI.Mass | weight (from PK_1C) | 75 | patient weight (kg) |
| Modelica.Units.SI.SpecificVolume | VdPerKg (from PK_1C) | 0.9 | Volume of distribution (L/kg) |
| Modelica.Units.SI.MassFraction | F (from PK_1C) | 0.8 | bioavailiability (0-1) |
| Pharmacolibrary.Types.Clearance | Cl (from PK_1C) | 20 | clearance |
| Modelica.Units.SI.Time | adminTime (from PK_1C) | 60 | first administration time (s) |
| Modelica.Units.SI.Time | adminDuration (from PK_1C) | 600 | administration duration (s) |
| Modelica.Units.SI.Time | adminPeriod (from PK_1C) | 8*60*60 | period of administration (default 8 hours)(s) |
| Pharmacolibrary.Types.Mass | adminMass (from PK_1C) | 1000 | administration mass (mg) |
| Integer | adminCount (from PK_1C) | 8 | number of dose administered (1) |
| Pharmacolibrary.Types.Volume | Vd (from PK_1C) | VdPerKg*weight | Volume of distribution (m3) |
| Pharmacolibrary.Types.MassConcentration | Cmin (from PK_1C) | 0.004 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Cmax (from PK_1C) | 0.008 | minimal therapeutic range |
| Pharmacolibrary.Types.MassConcentration | Ctox_peak (from PK_1C) | 0.012 | toxicity peak level |
| Pharmacolibrary.Types.MassConcentration | Ctox_trough (from PK_1C) | 0.006 | toxicity trough level |
Connectors
| Type | Name | Default | Description |
|---|---|---|---|
| Types.ConcentrationOutput | C_central (from PK_1C) | ||
| Interfaces.ConcentrationPort_b | centralCPort (from PK_1C) |
Components
| Type | Name | Default | Description |
|---|---|---|---|
| Pharmacokinetic.NoPerfusedTissueCompartment | central (from PK_1C) | ||
| Pharmacokinetic.ClearanceDrivenElimination | elim (from PK_1C) | ||
| Sources.PeriodicDose | periodicDose (from PK_1C) | ||
| Modelica.Units.SI.Time | t1_2 (from PK_1C) | elimination half-life |
Revisions
- 06/2025 Tomas Kulhanek, generated model from data extracted from PUBMED, DrugBank and LLM(GPT4.1)